Aileron Therapeutics logo

Aileron TherapeuticsNASDAQ: ALRN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 June 2017

Next earnings report:

15 April 2025

Last dividends:

N/A

Next dividends:

N/A
$86.88 M
-19%vs. 3y high
42%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Mon, 28 Oct 2024 21:56:17 GMT
$4.01+$0.29(+7.94%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ALRN Latest News

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
prnewswire.com12 October 2024 Sentiment: POSITIVE

First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term AUSTIN, Texas , Oct. 12, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the presentation of two abstracts detailing LTI-03's pre-clinical and Phase 1b (NCT05954988) results in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF). The Company previously  announced positive data  from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in patients with IPF.

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
prnewswire.com23 September 2024 Sentiment: POSITIVE

Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect AUSTIN, Texas , Sept. 23, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the completion of enrollment in Cohort 2 of the ongoing Phase 1b clinical trial of LTI-03 in IPF patients.

Aileron Therapeutics to Present at the 8th Annual IPF Summit
prnewswire.com19 August 2024 Sentiment: POSITIVE

AUSTIN, Texas , Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
prnewswire.com14 August 2024 Sentiment: POSITIVE

Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas , Aug. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a pipeline of potential first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "Throughout the first half of the year, we focused on strengthening our balance sheet and advancing the development of inhaled LTI-03 in IPF," said Brian Windsor, Ph.D.

Aileron Therapeutics to be Included in the Russell Microcap® Index
prnewswire.com01 July 2024 Sentiment: POSITIVE

AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization.

Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
Zacks Investment Research04 April 2023 Sentiment: POSITIVE

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

What type of business is Aileron Therapeutics?

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

What sector is Aileron Therapeutics in?

Aileron Therapeutics is in the Healthcare sector

What industry is Aileron Therapeutics in?

Aileron Therapeutics is in the Biotechnology industry

What country is Aileron Therapeutics from?

Aileron Therapeutics is headquartered in United States

When did Aileron Therapeutics go public?

Aileron Therapeutics initial public offering (IPO) was on 29 June 2017

What is Aileron Therapeutics website?

https://www.aileronrx.com

Is Aileron Therapeutics in the S&P 500?

No, Aileron Therapeutics is not included in the S&P 500 index

Is Aileron Therapeutics in the NASDAQ 100?

No, Aileron Therapeutics is not included in the NASDAQ 100 index

Is Aileron Therapeutics in the Dow Jones?

No, Aileron Therapeutics is not included in the Dow Jones index

When was Aileron Therapeutics the previous earnings report?

No data

When does Aileron Therapeutics earnings report?

The next expected earnings date for Aileron Therapeutics is 15 April 2025